Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
03 2023
Historique:
entrez: 6 3 2023
pubmed: 7 3 2023
medline: 9 3 2023
Statut: epublish

Résumé

In an analysis of risk evaluation and mitigation strategies for teratogenic drugs, Ameet Sarpatwari, Beatrice Brown and Aaron Kesselheim explore the variation in primary and secondary prevention measures.

Identifiants

pubmed: 36877723
doi: 10.1371/journal.pmed.1004190
pii: PMEDICINE-D-22-02031
pmc: PMC9987786
doi:

Substances chimiques

Teratogens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1004190

Informations de copyright

Copyright: © 2023 Brown et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: ASK is a member of the Editorial Board of PLOS Medicine.

Références

Matern Child Health J. 2020 Jul;24(7):901-910
pubmed: 32372243
MMWR Recomm Rep. 2016 Jul 29;65(4):1-66
pubmed: 27467319
JAMA Netw Open. 2022 Jan 4;5(1):e2144386
pubmed: 35050352
Am J Med Genet C Semin Med Genet. 2011 Aug 15;157C(3):175-82
pubmed: 21766440
N Engl J Med. 2018 Sep 20;379(12):1097-1099
pubmed: 30231220
Drug Saf. 2021 Jul;44(7):743-751
pubmed: 33904111
Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808
pubmed: 22556106
Am Fam Physician. 2010 Sep 15;82(6):621-8
pubmed: 20842989
Hum Reprod. 2011 Jan;26(1):106-11
pubmed: 20961942
JAMA. 2019 Feb 19;321(7):651-653
pubmed: 30778584
JAMA Dermatol. 2019 Oct 01;155(10):1175-1179
pubmed: 31314041
Drug Saf. 2017 Apr;40(4):333-341
pubmed: 28074423
Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1013-8
pubmed: 23893932
BMJ Qual Saf. 2020 Aug;29(8):636-644
pubmed: 31649165
J Gynecol Obstet Hum Reprod. 2019 May;48(5):297-307
pubmed: 30796985
Hosp Pharm. 2019 Oct;54(5):309-313
pubmed: 31555006
Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):324-8
pubmed: 23359404

Auteurs

Beatrice L Brown (BL)

Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.

Aaron S Kesselheim (AS)

Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.

Ameet Sarpatwari (A)

Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH